Company intelligence / Profile preview

Iconic Therapeutics, Inc.

South San Francisco, California, United Statesiconictherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Iconic Therapeutics has developed tissue factor-targeting therapeutics including XB002 (formerly ICON-2), which has shown promising preclinical results in solid tumors with better potency and tolerability compared to other TF-targeting antibody-drug conjugates[9][10]

Therapeutic areas: OphthalmologyOncology
Modalities: Monoclonal antibodyTissue Factor inhibitors
Industry: Biotech

Partnerships

Exelixis (licensed tissue factor-targeting antibody-drug conjugate XB002/ICON-2)[9]

Beyond the preview

Go deeper on Iconic Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iconic Therapeutics, Inc..